In a study of 154 people with this type of rectal cancer who were treated with dostarlimab, 68% had a complete clinical response at one year, which meant doctors could not see evidence of tumors on imaging or other methods for tracking the tumors.
—
Alice Park,
Time,
21 Oct. 2026
What was more, the data suggested that going after the therapy’s bull’s-eye might unlock the power of immunotherapy in other, more common cancers that had stubbornly rebuffed such efforts, like pancreatic and ovarian tumors.
Now researchers are investigating whether certain cancers, such as breast cancer, could be added to that list.
—
Lori Youmshajekian,
Scientific American,
8 June 2026
Over time, follow-on R&D added over 40 indications across numerous cancers — including early-stage applications that allow treatment to begin before cancer worsens.
Examples are automatically compiled from online sources to
show current usage.Read More
Opinions expressed in the examples do not represent those of Merriam-Webster or its editors.
Send us feedback.